GlassScriptPhysician profile
Robert Francis Rodriguez
NPI 1265883177
$2,960.66
in general payments reported to CMS, 2019-2025
18 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.51 · 2020: $227 · 2021: $151 · 2022: $39.15 · 2023: $265 · 2024: $859 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $596.59 | 2021-2025 | Aveir, Gallant, Assurity |
| Medtronic, INC. | $408.87 | 2023-2025 | Sonicision, Aurora Ev-Icd Mri Surescan, Onyx Frontier |
| Boston Scientific Corporation | $383.34 | 2020-2025 | Watchman Flx, Eluvia, Ranger |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $317.33 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $230.39 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $188.32 | 2024-2025 | Repatha |
| Pbg Puerto Rico LLC | $132.85 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.61 | 2019-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $115.09 | 2021-2024 | Xarelto |
| Pfizer INC. | $88.66 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.07 | 2024-2025 | Jardiance |
| Edwards Lifesciences Corporation | $83.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $76.51 | 2024-2025 | |
| Gilead Sciences, INC. | $40.91 | 2021 | |
| Glaxosmithkline, LLC. | $31.83 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.06 | 2025 | Winrevair |
| Bayer Puerto Rico INC. | $16.73 | 2025 | Kerendia |
| Scpharmaceuticals INC. | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.